在有或没有功能恶化的心力衰竭患者中,启动输血和短期改善心血管功能
Xinyu Zhang1,2,3, Wei Zhou4, Hui Liu5
1Cardiovascular Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Frontiers in cardiovascular medicine
|September 17, 2025
概括
在心力衰竭 (HF) 和不同程度的功能障碍患者中,威瑞西瓜特改善了心脏功能. 这种可溶性酸环酶刺激剂在所有功能组中都显示出好处,因此需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一个全球性的健康问题,由心脏和脏相互作用加剧.
- 作为一种可溶性酸环酶 (sGC) 刺激剂的vericiguat已被批准用于心力衰竭与减少射出分数 (HFrEF) 的治疗.
- 这项研究调查了 vericiguat 对心脏功能的影响 在HF 患有功能障碍的患者中.
研究的目的:
- 评估从医院内输血器开始的短期心脏功能改善.
- 为了评估transceiverguat在功能分层的HF患者的疗效.
- 分析心血管不良事件和左心室喷射率 (LVEF) 变化.
主要方法:
- 对401名HF患者进行了回顾性队列研究,该研究始于 vericiguat.
- 倾向性得分匹配 (PSM) 将队列改进为3个功能组中的217名患者.
- 主要终点:一年内发生3次主要心血管不良事件 (3P-MACE). 二级终点:六个月后的LVEF变化.
主要成果:
- 经过六个月的治疗,维里西瓜特疗法显著改善了LVEF,总体为11.8% (p < 0.001).
- 严重功能障碍组显示出最大的LVEF增加 (20.2%,p = 0.044).
- 在严重功能障碍组中观察到更低的生存概率和更高心血管事件风险的趋势.
结论:
- 维里西瓜特可以提高HF患者的心脏功能,无论脏状况如何.
- 这些发现支持进一步调查HF患者患有病并发症的 vericiguat.
- 优化对心脏与脏并发症的治疗策略至关重要.
更多相关视频
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.7K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.9K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:22Heart Failure Drugs: Diuretics
809
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
809
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:26Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
01:22Heart Failure Drugs: β-Blockers
772
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
772